Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for the quarter ended 30 September 2019 and provided an update on its clinical activities.
For more information, please refer to the English or Chinese press release.